Efficacy of Low-dose (10 mg) Rosuvastatin in Korean 4 Statin Benefit Groups Per 2013 ACC/AHA Guideline
Efficacy of Low-dose (10 mg) Rosuvastatin in Korean 4 Statin Benefit Groups Per 2013 ACC/AHA Guideline
This study aimed to evaluate the efficacy of low-dose rosuvastatin (10 mg) in the 4 statin
 benefit groups requiring high- or moderate-intensity statin therapy according to the 2013
 American College of Cardiology/American Heart Association guideline in Korean population.
The primary endpoint was percentage reduction in low-density lipoprotein (LDL) cholesterol.
 Secondary endpoints were percentage reduction in other lipids and achievement of ≥50%
 reduction in LDL cholesterol. Intention-to-treat analyses were performed.
Inclusion Criteria:

 1. subjects with prior history of clinical ASCVD

 2. subjects with primary elevation of LDL cholesterol ≥190 mg/dL

 3. subjects with diabetes, age 40 to 75 years, and LDL cholesterol 70 to 189 mg/dL

 4. subjects without diabetes, age 40 to 75 years, LDL cholesterol 70 to 189 mg/dL, and
 with estimated 10-year ASCVD risk ≥7.5%.

 Exclusion Criteria:

 1. history of significant statin-induced rhabdomyolysis or myopathy

 2. history of a significant hypersensitivity reaction to rosuvastatin

 3. uncontrolled diabetes mellitus (HbA1c >9%)

 4. uncontrolled hypertension (systolic blood pressure >190 mmHg or diastolic blood
 pressure >100 mmHg)

 5. current active liver disease (alanine aminotransferase and/or aspartate
 aminotransferase >2 times the upper limit of normal)

 6. chronic kidney disease (serum creatinine clearance <30 ml/min)

 7. creatine kinase levels >3 times the upper limit of normal

 8. use of prohibited concomitant therapies

 9. history of malignancy within the last 5 years

 10. women who were pregnant, breast-feeding or of childbearing potential without
 contraception

 11. subjects who would take any medication for purposes other than this trial within 30
 days after taking this study's medication.